Results 91 to 100 of about 79,283 (266)
Combined redifferentiation via HDAC inhibitor and MAPK inhibitor in thyroid cancer cells
Background and purpose: Redifferentiation therapy with MAPK inhibitor is a novel strategy for radioiodine-refractory differentiated thyroid cancer, but its efficacy is relatively low.
程凌霄, 靳雨辰
doaj
Background: Treatment of recurrent chemotherapy, aromatase (AI) and MEK Inhibitor (MEKi) resistant low grade serous ovarian cancer (LGSOC) remains a challenge. Novel treatment options for KRAS mutated MEKi resistant LGSOC are warranted.
Victoria M. Ettorre +4 more
doaj +1 more source
Cutaneous Rosai‐Dorfman Disease With MAP2K1 Mutation Treated With Encorafenib and Binimetinib
ABSTRACT Rosai‐Dorfman disease (RDD) is a rare histiocytic disorder with unifocal to multisystemic involvement. Activating mutations in the MAPK/ERK pathway can occur in up to 50% of RDD cases. We report a case of cutaneous RDD (C‐RDD) with facial and truncal lesions harboring an activating MAP2K1 (MEK1) mutation that showed a complete response to a ...
Melike Ak +2 more
wiley +1 more source
Oncogenic KRAS Rewires Stress Granule Dynamics: Mechanisms and Therapeutic Opportunities
ABSTRACT Stress granules (SGs) are dynamic, membrane‐less structures that form in response to various cellular stresses, including metabolic, oxidative, and therapeutic challenges. They function as adaptive hubs and reorganize protein synthesis and signaling networks to help cells survive under stress. In cancer, these condensates are often hijacked to
Msimisi Ndzinisa +2 more
wiley +1 more source
MEK Inhibitor Associated Airway Injury in an Infant With Noonan Syndrome: A Case Report
An infant with Noonan syndrome treated with trametinib developed extensive mucosal sloughing of the upper and lower airway, followed by severe supraglottic scarring. Clinicians should consider airway toxicity as a potential adverse effect of MEK inhibitor therapy.
Veronica Drozdowski‐Nuccio +4 more
wiley +1 more source
Hsp90 Inhibition on the Western Blot: N‐Terminal Versus C‐Terminal Inhibitors in Breast Cancer
ABSTRACT Heat shock protein 90 (Hsp90) is an established and clinically validated anticancer target. By regulating the folding and maturation of diverse client proteins, it is indirectly involved in carcinogenesis. Key breast cancer oncogenic drivers, including estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, are ...
Jaka Dernovšek +3 more
wiley +1 more source
The FGF/FGFR System in the Biology and Therapeutic Landscape of Pediatric CNS Tumors
ABSTRACT Central nervous system (CNS) tumors are the most common solid malignancies in children, comprising a highly heterogeneous group of neoplasms defined by distinct molecular alterations and clinical behaviors. Advances in molecular genetics have underscored the relevance of specific signaling pathways in driving pediatric tumorigenesis, among ...
Serena Filiberti +6 more
wiley +1 more source
Navigating the Complexity: A Comprehensive Review of GSK‐3 Inhibition in Regenerative Medicine
ABSTRACT Glycogen synthase kinase‐3 (GSK‐3) is a central regulator of numerous cellular signaling pathways, with critical roles in metabolism, proliferation, differentiation, and tissue regeneration. This review explores the multifaceted effects of pharmacological GSK‐3 inhibition across multiple body districts, focusing on its highly context‐dependent
Davide Schiroli +5 more
wiley +1 more source
Cysteine protease inhibitor 1 (CST1) is a cystatin superfamily protein that inhibits cysteine protease activity and is reported to be involved in the development of many malignancies.
Liangming Zhang +9 more
doaj +1 more source
ECM, extracellular matrix; BDNF, brain‐derived neuroptrophic factor; FGF, fibroblast growth factor; VEGF, vascular endothelial growth factor. Abstract Heparan sulfate, a structurally diverse glycosaminoglycan that is abundant in the central nervous system (CNS), orchestrates essential processes fundamental to neural plasticity, neurorepair, and ...
Mozammel H. Bhuiyan +3 more
wiley +1 more source

